Concepedia

Hitoshi Arioka

HA

Statistics

Publications

40

Citations

1.5K

H-Index

21

Active since

1993

Affiliations

Yokohama Rosai Hospital(Current)

National Cancer Research Institute

National Cancer Center Hospital East

Shizuoka Cancer Center

National Cancer Center

Hitoshi Arioka is an author at Yokohama Rosai Hospital specializing in oncology, medicine, and pharmacology.

Publications per year

1993–2023

40

Publications

40

Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Masatoshi Kudo, Ann‐Lii Cheng, Joong‐Won Park et al. · The Lancet. Gastroenterology & hepatology · 2017 · 196 citations

Medicine, Oncology, Pharmacology +15

Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.

Minoru Fukuda, Kohei Nishio, Fumihiko Kanzawa et al. · PubMed · 1996 · 156 citations

Medicine, Oncology, Pharmacology +16

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

Fumihiko Kanai, Haruhiko Yoshida, Ryosuke Tateishi et al. · Cancer Chemotherapy and Pharmacology · 2010 · 97 citations · Full text

Medicine, Oncology, Pharmacology +13

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

Tatsunori Shimoi, Shigenori E. Nagai, Tetsuhiro Yoshinami et al. · Breast Cancer · 2020 · 76 citations · Full text

Medicine, Oncology, Breast Oncology +11

Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy

Yuka Ito, Takashi Tsuda, Hiroko Minatogawa et al. · Journal of Clinical Oncology · 2018 · 72 citations

Medicine, Oncology, Pharmacology +11

1–5 of 40